Digital RESI Innovation Challenge

Vote for Me

Interested in Connecting? Please contact:
Natalia Mitin
CEO
natalia.mitin@sapere-bio.com

Message the company or request a 1:1 meeting here

Sapere Bio is a clinical-stage diagnostics company translating the science of aging and cellular senescence into risk prediction reports that, for the first time, quantitate risk of adverse health outcomes based on unseen risk inherent to the patient. Our first indication is cardiovascular surgery, where our product, AKI-Sapere, can identify patients at risk for acute kidney injury, a devastating and common complication leading to $1B in additional hospital costs. AKI-Sapere is a first-in-class, pre-operative blood test that will be launched in select hospitals in Q3-2021. Development and validation of the product have been supported solely by a non-dilutive funds and we are raising a Series A round to support launch.

Pitch Video